A. Schmiderer

Most-cited papers

1. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

   M. S. Rezaee-Zavareh, Y. Yeo, Tie-Long Wang, Zhi-Yong Guo +41 more

   2024Journal of Hepatology107 citations

   Semantic Scholar

   Save

2. Fecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2 - a comparative study.

   A. Zollner, A. Schmiderer, S. Reider, G. Oberhuber +8 more

   2020Journal of Crohn's & Colitis85 citations

   Semantic Scholar

   Save

3. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.

   B. Moeckli, C. Wassmer, S. El Hajji, Rohan Kumar +24 more

   2025Hepatology43 citations Open access

   Semantic Scholar

   Save

4. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

   S. Welland, C. Leyh, F. Finkelmeier, A. Jefremow +25 more

   2022Liver Cancer39 citations Open access

   Semantic Scholar

   Save

5. Decline in acute upper gastrointestinal bleeding during COVID-19 pandemic after initiation of lockdown in Austria

   A. Schmiderer, H. Schwaighofer, L. Niederreiter, C. Profanter +3 more

   2020Endoscopy27 citations Open access

   Semantic Scholar

   Save

6. Obesity and Its Impact on Transplantation and Alloimmunity

   T. Heinbokel, B. Floerchinger, A. Schmiderer, K. Edtinger +3 more

   2013Transplantation22 citations Open access

   Semantic Scholar

   Save

7. Liver Transplantation after Successful Downstaging of a Locally Advanced Hepatocellular Carcinoma with Systemic Therapy

   A. Schmiderer, H. Zoller, M. Niederreiter, M. Effenberger +6 more

   2023Digestive Diseases18 citations

   Semantic Scholar

   Save

8. Colorectal cancer screening and prevention—pros and cons

   M. Niederreiter, L. Niederreiter, A. Schmiderer, H. Tilg +1 more

   2019memo - Magazine of European Medical Oncology15 citations Open access

   Semantic Scholar

   Save

9. Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort

   Tiago de Castro, S. Welland, L. Jochheim, Cathrine Leyh +34 more

   2024Hepatology Communications11 citations Open access

   Semantic Scholar

   Save

10. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

    H. Taghizadeh, M. Unseld, A. Schmiderer, A. Djanani +3 more

    2020Cancer Chemotherapy and Pharmacology9 citations Open access

    Semantic Scholar

    Save

11. Gut microbiome-immune crosstalk affects progression of cancer.

    H. Tilg, A. Schmiderer, A. Djanani

    2018Translational Gastroenterology and Hepatology8 citations Open access

    Semantic Scholar

    Save

12. Management of ductal pancreatic cancer

    A. Djanani, A. Schmiderer, L. Niederreiter, M. Niederreiter +1 more

    2019European surgery2 citations Open access

    Semantic Scholar

    Save

13. Gemcitabine related pneumonitis (GRP) in patients with pancreatic ductal adenocarcinoma (PDAC) – A case series

    A. Schmiderer, M. Niederreiter, L. Niederreiter, AM Djanani +1 more

    2019Zeitschrift für Gastroenterologie - German Journal of Gastroenterology1 citations

    Semantic Scholar

    Save

14. P-48 First evidence for the antitumor activity of nanoliposomal irinotecan in metastatic biliary tract cancer

    H. Taghizadeh, M. Unseld, A. Schmiderer, D. Buchinger +2 more

    20200 citations Open access

    Semantic Scholar

    Save

15. Malignant peritoneal Mesothelioma: prolonged unexplained CRP" – A case series

    A. Djanani, A. Djanani, A. Schmiderer, L. Niederreiter +2 more

    2019Zeitschrift für Gastroenterologie - German Journal of Gastroenterology0 citations

    Semantic Scholar

    Save